Phase 2 trial reveals Lixisenatide may reduce motor disability in Parkinson’s patients Post author: Post published:April 18, 2024 Post category:uncategorized A trial of lixisenatide to assess its effects in early Parkinson’s disease. You Might Also Like How do animal and plant-based milks affect gut health? September 17, 2024 Daily toothbrushing in hospitals linked to significant drop in pneumonia cases and ICU mortality rates December 19, 2023 Balance on one leg may be the best indicator of neuromuscular aging, new study suggests October 29, 2024
Daily toothbrushing in hospitals linked to significant drop in pneumonia cases and ICU mortality rates December 19, 2023
Balance on one leg may be the best indicator of neuromuscular aging, new study suggests October 29, 2024